Skip to main content

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

*March 2022*

  • The EGFR-TKI efficacy of uncommon EGFR mutations generally considered TKI-sensitive was validated.
  • Complex EGFR mutations containing exon19del or L858R mutations were EGFR TKI sensitive, independent of the combination partner.
  • Very rare single and complex mutations, comprising 40% of atypical mutations, show a high heterogeneity of TKI sensitivity.
  • TP53 co-mutations may confer a detrimental outcome in TKI treated patients with very rare EGFR mutations and exon20ins.
  • We propose a novel nNGM classification for rare EGFR mutations.

Read more.